A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium.
作者信息
Sun Weili, Triche Timothy, Malvar Jemily, Gaynon Paul, Sposto Richard, Yang Xiaojing, Bittencourt Henrique, Place Andrew E, Messinger Yoav, Fraser Chris, Dalla-Pozza Luciano, Salhia Bodour, Jones Peter, Wayne Alan S, Gore Lia, Cooper Todd M, Liang Gangning
机构信息
Department of Pediatrics, City of Hope National Medical Center, Duarte, CA.
Children's Center for Cancer and Blood Diseases, Children Hospital Los Angeles, Los Angeles, CA.
出版信息
Blood. 2018 Mar 8;131(10):1145-1148. doi: 10.1182/blood-2017-09-803809. Epub 2018 Jan 16.
Abstract
摘要
相似文献
1
A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium.阿扎胞苷联合化疗用于儿童白血病的1期研究：TACL联盟的报告
Blood. 2018 Mar 8;131(10):1145-1148. doi: 10.1182/blood-2017-09-803809. Epub 2018 Jan 16.
2
Venetoclax with decitabine or azacitidine for AML.维奈托克联合地西他滨或阿扎胞苷治疗急性髓系白血病
Lancet Oncol. 2018 Dec;19(12):e672. doi: 10.1016/S1470-2045(18)30824-6. Epub 2018 Nov 1.
3
Hypomethylating agents and venetoclax in acute myeloid leukemia.急性髓系白血病中的去甲基化药物与维奈克拉
Clin Adv Hematol Oncol. 2021 Feb;19(2):82-83.
4
Low-dose cytarabine and hypomethylating agents for Down syndrome with acute myeloid leukemia.低剂量阿糖胞苷和低甲基化药物用于唐氏综合征合并急性髓系白血病的治疗
Pediatr Blood Cancer. 2024 Jun;71(6):e30974. doi: 10.1002/pbc.30974. Epub 2024 Mar 24.
5
Phase 1-2 safety, efficacy and pharmacokinetic study of decitabine in sequential administration with cytarabine in children with relapsed or refractory acute myeloid leukaemia.地西他滨与阿糖胞苷序贯给药用于复发或难治性急性髓性白血病儿童的1-2期安全性、疗效及药代动力学研究
Br J Haematol. 2019 Aug;186(3):e7-e11. doi: 10.1111/bjh.15847. Epub 2019 Mar 7.
6
How I treat older patients with acute myeloid leukemia.我如何治疗老年急性髓系白血病患者。
Cancer. 2018 Jun 15;124(12):2472-2483. doi: 10.1002/cncr.31347. Epub 2018 May 29.
7
A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia.一项avelumab联合地西他滨作为不适合进行一线治疗的急性髓系白血病患者的I期临床试验。
Am J Hematol. 2021 Feb 1;96(2):E46-E50. doi: 10.1002/ajh.26043. Epub 2020 Nov 23.
8
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study.维奈克拉联合阿扎胞苷或地西他滨治疗新诊断的急性髓系白血病患者：来自 1b 期研究的长期随访。
Am J Hematol. 2021 Feb 1;96(2):208-217. doi: 10.1002/ajh.26039. Epub 2020 Nov 10.
9
Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.阿扎胞苷与地西他滨治疗骨髓增生异常综合征和急性髓系白血病的比较：网状荟萃分析。
Clin Lymphoma Myeloma Leuk. 2021 Jun;21(6):e530-e544. doi: 10.1016/j.clml.2021.01.024. Epub 2021 Feb 24.
10
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.在未经治疗的老年急性髓系白血病患者中，venetoclax 联合地西他滨或阿扎胞苷的安全性和初步疗效：一项非随机、开放标签、1b 期研究。
Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12.
引用本文的文献
1
Oncogenic and immunological targets for matched therapy of pediatric blood cancer patients: Dutch iTHER study experience.儿童血癌患者匹配治疗的致癌和免疫靶点：荷兰iTHER研究经验
Hemasphere. 2024 Jul 15;8(7):e122. doi: 10.1002/hem3.122. eCollection 2024 Jul.
2
Azacitidine as epigenetic priming for chemotherapy is safe and well-tolerated in infants with newly diagnosed -rearranged acute lymphoblastic leukemia: Children's Oncology Group trial AALL15P1.阿扎胞苷作为化疗的表观遗传启动剂，对于新诊断的重排急性淋巴细胞白血病婴儿是安全且耐受性良好的：儿童肿瘤学组试验AALL15P1。
Haematologica. 2024 Dec 1;109(12):3918-3927. doi: 10.3324/haematol.2024.285158.
3
Aberrant stem cell and developmental programs in pediatric leukemia.小儿白血病中的异常干细胞和发育程序
Front Cell Dev Biol. 2024 Mar 27;12:1372899. doi: 10.3389/fcell.2024.1372899. eCollection 2024.
4
Mutations of epigenetic modifier genes predict poor outcome in adult acute lymphoblastic leukemia.表观遗传学修饰基因的突变可预测成人急性淋巴细胞白血病的不良预后。
Ann Hematol. 2024 Sep;103(9):3639-3648. doi: 10.1007/s00277-024-05681-4. Epub 2024 Mar 7.
5
miR-1202 acts as anti-oncomiR in myeloid leukaemia by down-modulating GATA-1 expression.miR-1202 通过下调 GATA-1 的表达在髓性白血病中发挥抑癌作用。
Open Biol. 2024 Feb;14(2):230319. doi: 10.1098/rsob.230319. Epub 2024 Feb 14.
6
Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium.纳武单抗联合5-阿扎胞苷治疗儿童复发/难治性急性髓系白血病（AML）：儿童白血病和淋巴瘤治疗进展（TACL）联盟的I/II期试验结果
Cancers (Basel). 2024 Jan 24;16(3):496. doi: 10.3390/cancers16030496.
7
An Overview of Advances in Rare Cancer Diagnosis and Treatment.罕见癌症诊断与治疗进展概述。
Int J Mol Sci. 2024 Jan 18;25(2):1201. doi: 10.3390/ijms25021201.
8
Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712.在儿科复发/难治性 AML 中联合使用pevonedistat 联合阿扎胞苷、氟达拉滨、阿糖胞苷的可行性：COG ADVL1712 的结果。
Pediatr Blood Cancer. 2023 Dec;70(12):e30672. doi: 10.1002/pbc.30672. Epub 2023 Sep 14.
9
Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy.细胞组成和 5hmC 特征可预测 AML 患者接受阿扎胞苷联合化疗的治疗反应。
Adv Sci (Weinh). 2023 Aug;10(23):e2300445. doi: 10.1002/advs.202300445. Epub 2023 Jun 4.
10
Translational advances in the treatment of childhood acute lymphoblastic leukemia: narrative review of current and emerging molecular and immunotherapies.儿童急性淋巴细胞白血病治疗的转化进展：对当前及新兴分子和免疫疗法的叙述性综述
Transl Pediatr. 2023 Mar 31;12(3):487-502. doi: 10.21037/tp-22-656. Epub 2023 Feb 24.
本文引用的文献
1
A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML.一项多中心、随机研究，评估地西他滨作为表观遗传学诱导剂联合诱导化疗治疗儿童急性髓系白血病的效果。
Clin Epigenetics. 2017 Oct 5;9:108. doi: 10.1186/s13148-017-0411-x. eCollection 2017.
2
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses.抑制DNA甲基化会通过包括内源性逆转录病毒在内的双链RNA在癌症中引发干扰素反应。
Cell. 2015 Aug 27;162(5):974-86. doi: 10.1016/j.cell.2015.07.011.
3
De novo identification of differentially methylated regions in the human genome.人类基因组中差异甲基化区域的从头识别。
Epigenetics Chromatin. 2015 Jan 27;8:6. doi: 10.1186/1756-8935-8-6. eCollection 2015.
4
Gene body methylation can alter gene expression and is a therapeutic target in cancer.基因体甲基化可改变基因表达，是癌症治疗的一个靶点。
Cancer Cell. 2014 Oct 13;26(4):577-90. doi: 10.1016/j.ccr.2014.07.028. Epub 2014 Sep 25.
5
Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group.儿童复发性急性髓系白血病的改善结局：国际 BFM 研究组进行的脂质体柔红霉素随机试验的结果。
J Clin Oncol. 2013 Feb 10;31(5):599-607. doi: 10.1200/JCO.2012.43.7384. Epub 2013 Jan 14.
6
Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia.表观遗传重编程逆转了儿童 B 淋巴细胞白血病复发特异性的基因表达特征，并恢复了对化疗的敏感性。
Blood. 2012 May 31;119(22):5201-10. doi: 10.1182/blood-2012-01-401687. Epub 2012 Apr 11.
7
A decade of exploring the cancer epigenome - biological and translational implications.一个探索癌症表观基因组的十年 - 生物学和转化意义。
Nat Rev Cancer. 2011 Sep 23;11(10):726-34. doi: 10.1038/nrc3130.
8
Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies.复发儿童急性淋巴细胞白血病的综合基因组分析揭示治疗策略。
Blood. 2011 Nov 10;118(19):5218-26. doi: 10.1182/blood-2011-04-345595. Epub 2011 Sep 14.
9
AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.AAML03P1 研究：吉妥珠单抗奥唑米星联合化疗治疗新诊断儿童急性髓系白血病的安全性初探：来自儿童肿瘤协作组的报告。
Cancer. 2012 Feb 1;118(3):761-9. doi: 10.1002/cncr.26190. Epub 2011 Jul 15.
10
Epigenetics in AML.AML 中的表观遗传学。
Best Pract Res Clin Haematol. 2010 Dec;23(4):463-8. doi: 10.1016/j.beha.2010.09.017. Epub 2010 Nov 1.
Zotero 插件